ICNTN Webinars & FLICNA Podcasts
Details
Ratings
July 17, 2025
Speaker: Pr Kaoutar Khabbache When: 17 juillet 2025 Time: 06:00 PM CET Click here to Register
July 12, 2025
Speaker: Yasmin Khakoo, MD, FCNS, FAAN, FAAP When: Saturday, July 12, 2025 Time: 09:00 AM Eastern Time ( US/ Canada ) Click here to Regsiter
July 19, 2025
Topic: Navigating MOGAD Landscape: Demyelination With Many Faces Lecturers: Javeria Raza Alvi (Speaker); Areeba Wasim (Speaker); Tipu Sultan (Expert Faculty); Amna Al Futaisi (Expert Faculty); Mohammad Raza (Moderator) When: Saturday, 19 July 2025 Time: 09:00 AM Eastern Time ( US/ Canada ) Click here to Register
June 21, 2025
Topic: Treating Ahead of Time: The Impact of Early Diagnosis in Treatable Pediatric Neurotransmitter Disorders Lecturers: Juhi Gupta (Moderator); Günce Başarır (Speaker); Elif Perihan Öncel (Speaker); Biju Hameed (Expert Faculty) When: Saturday, 21 June 2025 Time: 09:00 AM Eastern Time ( US/ Canada )
June 28, 2025
Speaker: Pinar Aydin O`Dwyer, When: Saturday, June 28th, 2025 Time: 09:00 AM Eastern Time ( US/ Canada )
June 19, 2025
Speaker: Banu Anlar When: jeudi, 19 Juin 2025 Time: 6:00 PM (CEST)
June 14, 2025
Speaker: Kirsty Donald When: Saturday, June 14, 2025 Time: 09:00 AM Eastern Time ( US/ Canada )
May 20, 2025
ICNA Advocacy Webinar Topic: Improving Diagnosis and Classification of Developmental and Epileptic Encephalopathies (DEEs) Speaker: Nicola Specchio When: May 20, 2025 Time: 1 pm CEST
May 31, 2025
Speaker: Dr. Haluk Topaloglu When: Saturday, May 31, 2025 Time: 9:00 AM EST
About Topic: Paintings of children as the centre of attention or theme, from different periods and cultures in time, from thousands of years BC up until our contemporary times.
May 21, 2025
Speaker: Pr Kumaran Deiva When: Mercredi, Mai 21, 2025 Time: 7 PM CEST About Topic: La SEP de l’enfant est reconnue de plus en plus précocement grâce à l'amélioration des critères diagnostiques (2017 IPMSSG). Les traitements de fond utilisés chez l’adulte sont désormais validés chez l’enfant : le fingolimod a été le premier approuvé pour les formes pédiatriques récurrentes. D’autres biothérapies comme le natalizumab ou l’ocrelizumab sont utilisées hors AMM avec des résultats prometteurs. La prise en charge actuelle repose sur une approche précoce, individualisée et multidisciplinaire, intégrant neurologie,...